Idiopathic Pulmonary Hemosiderosis

Etiology

The etiology of idiopathic pulmonary hemosiderosis remains incompletely understood and is likely multifactorial. Current evidence supports immune dysregulation as the predominant underlying mechanism, although a definitive unifying pathway has not been established (see Image. Immune-Mediated Pulmonary Hemosiderosis).[1][5] Idiopathic pulmonary hemosiderosis is therefore best conceptualized as a syndrome that may arise from heterogeneous triggers acting on a susceptible host.

Proposed contributing factors include environmental exposures, developmental vulnerability, and genetic or immune predisposition. Early epidemiologic studies suggested associations with toxic environmental exposures, including agricultural insecticides and indoor molds, eg, Stachybotrys chartarum. Notably, a cluster of infantile pulmonary hemorrhage cases in Cleveland in the 1990s was initially linked to Stachybotrys exposure; however, subsequent investigations failed to confirm a causal relationship, and this association remains unproven. Prematurity has also been reported more frequently among affected infants, although whether this reflects increased susceptibility or ascertainment bias is unclear.

The strongest and most reproducible evidence supports an immune-mediated basis. Idiopathic pulmonary hemosiderosis has been reported in association with multiple autoimmune conditions, including rheumatoid arthritis, autoimmune hemolytic anemia, thyroid disease, and celiac disease.[6] In some patients, idiopathic pulmonary hemosiderosis may precede the later development of systemic autoimmune disease, including antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, suggesting that idiopathic pulmonary hemosiderosis may represent an early or form fruste manifestation of immune-mediated pulmonary capillaritis in a subset of cases.[3]

Lane–Hamilton Syndrome

The coexistence of idiopathic pulmonary hemosiderosis and celiac disease, termed Lane–Hamilton syndrome, represents the most clinically significant and potentially modifiable association. The reported prevalence of celiac disease among patients with idiopathic pulmonary hemosiderosis varies widely across cohorts but is consistently higher than in the general population.[7][8] Importantly, gastrointestinal manifestations are frequently absent, and pulmonary symptoms may be the sole presentation; in one systematic review, only approximately 20% of patients had significant gastrointestinal symptoms at diagnosis.[8]

Gluten exposure is thought to trigger or exacerbate alveolar hemorrhage through immune-mediated mechanisms, and hemoptysis may be the only presenting symptom.[9] Notably, initiation of a strict gluten-free diet has been associated with clinical improvement and, in some cases, remission of pulmonary symptoms. Given these observations, routine serologic screening for celiac disease is recommended in all patients with suspected or confirmed idiopathic pulmonary hemosiderosis, regardless of gastrointestinal symptoms.

Other Associated Conditions and Diagnostic Considerations

Other conditions associated with idiopathic pulmonary hemosiderosis include:

• Down syndrome: Approximately 20% of pediatric idiopathic pulmonary hemosiderosis patients in the French RespiRare cohort have Down syndrome, with autoimmune markers present in up to 75% of these patients.[2] This likely reflects an underlying predisposition to immune dysregulation rather than a direct causal relationship.

• Kabuki syndrome (KMT2D/KDM6A mutations): Rarely reported association; limited data suggest a potential immune-mediated mechanism and responsiveness to immunosuppressive therapy, including methylprednisolone pulse therapy after failure of standard prednisolone.[10]

• Heiner syndrome: A non-IgE–mediated hypersensitivity to cow’s milk protein that can present with pulmonary hemosiderosis in infants and young children. This entity must be excluded before diagnosing idiopathic pulmonary hemosiderosis, as it represents a distinct and potentially reversible cause of diffuse alveolar hemorrhage.

• Evolution to systemic vasculitis: A subset of patients initially diagnosed with idiopathic pulmonary hemosiderosis later develop ANCA-associated vasculitis, reinforcing the concept that idiopathic pulmonary hemosiderosis may, in some cases, represent an early or incomplete autoimmune phenotype.[3]

Epidemiology

Due to the rare nature of idiopathic pulmonary hemosiderosis, the incidence and prevalence of the disease are relatively unknown. Many patients previously reported to have idiopathic pulmonary hemosiderosis were likely misclassified and would now fall under the broader category of DAH. A Swedish study from 1984 estimated an incidence of 0.24 cases per million children per year, using data collected from 1950 to 1979.[11] A retrospective study from Japan estimated approximately 1.23 cases per million per year.[12]

Approximately 80% of cases occur in children, most of whom are diagnosed in the first decade of life. However, this estimate is based on aggregated case series rather than population-based cohorts.[13] The largest multicenter international study of pediatric DAH to date, including 124 patients from 26 centers across 15 countries, identified idiopathic pulmonary hemosiderosis as the most frequent single diagnosis within pediatric DAH cohorts.[4] A parallel European multicenter analysis found that approximately 26% of all pediatric DAH patients had no identifiable etiology.[3]

Adult-onset idiopathic pulmonary hemosiderosis accounts for approximately 20% of cases; however, an unknown fraction may represent undiagnosed childhood-onset idiopathic pulmonary hemosiderosis. The gender distribution appears balanced in childhood-onset idiopathic pulmonary hemosiderosis, whereas adult-onset disease shows a male predominance. Adult data from a systematic review demonstrated a male predominance of 64.3% with a median age at diagnosis of 27 years.[5]

Additionally, familial clustering has been noted in several reports, suggesting a genetic component.[14][15][16] Diagnostic delay remains a significant problem: in a contemporary Chinese pediatric cohort, the mean time from symptom onset to diagnosis was 5 months (range 0.25–36 months), and the majority of patients were initially misdiagnosed, most commonly as iron-deficiency anemia or gastrointestinal bleeding.[17] 

Pathophysiology

Diffuse alveolar hemorrhage in idiopathic pulmonary hemosiderosis is characterized by recurrent leakage of erythrocytes into the alveolar spaces, followed by phagocytosis by alveolar macrophages. These macrophages degrade erythrocytes, leading to the accumulation of iron derived from heme metabolism. Intracellular iron is initially stored as ferritin and subsequently converted into hemosiderin within lysosomes. Over time, repeated hemorrhagic episodes result in progressive accumulation of hemosiderin-laden macrophages.

Although iron is sequestered within macrophages, systemic iron deficiency in idiopathic pulmonary hemosiderosis primarily reflects chronic, recurrent alveolar blood loss coupled with inefficient recycling of iron from pulmonary stores. Excess intracellular iron also contributes to lung injury. Iron can catalyze the formation of reactive oxygen species through redox cycling, leading to oxidative stress, epithelial and endothelial injury, and activation of pro-fibrotic pathways. Recurrent hemorrhage and oxidative injury together are thought to drive progressive alveolar damage and, in some cases, interstitial fibrosis.

Emerging Pathogenetic Mechanisms

A proposed mechanism suggests that diffuse alveolar hemorrhage in idiopathic pulmonary hemosiderosis may be mediated by bioactive proteins, including histamine, eosinophilic cationic protein (ECP), and vascular endothelial growth factor (VEGF), which may increase permeability of the alveolar-capillary barrier and facilitate erythrocyte extravasation.[18] This remains a hypothesis based on limited observational and review-level data rather than on established mechanistic evidence. This hypothesis may help explain the absence of immune complex deposition on immunofluorescence, a feature that distinguishes idiopathic pulmonary hemosiderosis from classic immune complex–mediated diffuse alveolar hemorrhage. However, current evidence remains limited, and this mechanism requires further validation.

Alveolar macrophages may also contribute to ongoing injury beyond iron accumulation by releasing proinflammatory mediators, thereby perpetuating a cycle of inflammation and hemorrhage.

Immune Dysregulation

Autoantibodies are detectable in approximately 26.4% of pediatric patients with idiopathic pulmonary hemosiderosis, with antinuclear antibodies (ANA) and antineutrophil cytoplasmic antibodies (ANCA) most commonly detected.[19] The prevalence appears lower in adults (~13.2%).[20] These data are derived from heterogeneous studies with variable antibody panels, titers, and timing of testing (often after treatment initiation), which limits causal interpretation. These findings support a role for immune dysregulation, even in the absence of overt systemic autoimmune disease at presentation, and raise the possibility that idiopathic pulmonary hemosiderosis may represent an early or incomplete autoimmune phenotype in a subset of patients.

Classification of Pulmonary Hemosiderosis

Pulmonary hemosiderosis is traditionally categorized into 3 groups based on underlying pathophysiology:

• Group 1: Antiglomerular basement membrane (anti-GBM) disease
  • Characterized by circulating anti-GBM antibodies leading to small-vessel vasculitis with linear deposition of immunoglobulin G along basement membranes. This includes Goodpasture syndrome, in which pulmonary hemorrhage is often accompanied by rapidly progressive glomerulonephritis.
  • Approximately 40% to 60% of patients develop alveolar hemorrhage. Diagnosis is typically established by a kidney biopsy demonstrating linear IgG deposition on immunofluorescence rather than a lung biopsy.[21][22] 
• Group 2: Immune-mediated diffuse alveolar hemorrhage (capillaritis-predominant)
  • Caused by inflammatory injury to the alveolar capillary bed, often mediated by small-vessel vasculitis rather than classic immune complex deposition alone. This results in capillaritis, disruption of the alveolar-capillary barrier, and hemorrhage. Recurrent injury can lead to fibrosis.
  • Associated conditions include systemic lupus erythematosus, IgA vasculitis (Henoch–Schönlein purpura), ANCA-associated vasculitides (eg, granulomatosis with polyangiitis, microscopic polyangiitis), and mixed connective tissue disease.[23][24][25]
• Group 3: Idiopathic pulmonary hemosiderosis
  • Defined by recurrent alveolar hemorrhage in the absence of identifiable immune-mediated, infectious, cardiovascular, or structural causes.
  • Idiopathic pulmonary hemosiderosis remains a diagnosis of exclusion. A descriptive subclassification has been proposed, grouping patients based on features, eg, autoimmune markers, eosinophilia, renal involvement, or multiorgan disease, which may have implications for prognosis and management.[3] 

Histopathology

Histopathologic findings in idiopathic pulmonary hemosiderosis vary according to the stage and chronicity of disease progression. Early or acute phases demonstrate intra-alveolar hemorrhage with accumulation of erythrocytes and numerous hemosiderin-laden macrophages within the alveolar spaces. Hemosiderin deposition may also extend into the interstitium. Recurrent or chronic hemorrhagic episodes promote progressive interstitial thickening and fibrosis, reflecting persistent cycles of pulmonary injury and repair.

The hallmark histopathologic characteristic of idiopathic pulmonary hemosiderosis involves a pattern of “bland” alveolar hemorrhage rather than a distinct pathognomonic lesion. Pulmonary capillaritis remains absent, with no neutrophilic infiltration, fibrinoid necrosis of the alveolar septa, or leukocytoclasia identified on histologic examination. Immunofluorescence studies also demonstrate negative findings for immune complex or immunoglobulin deposition.

These negative histopathologic findings are of substantial diagnostic importance because they help distinguish idiopathic pulmonary hemosiderosis from alternative causes of diffuse alveolar hemorrhage, including antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, anti-GBM disease, and connective tissue disease–associated capillaritis. Interpretation nevertheless requires caution, as sampling error may occur and inflammatory features may occasionally be obscured in early-stage or previously treated disease.

History and Physical

The clinical presentation of idiopathic pulmonary hemosiderosis varies from an acute onset illness with hemoptysis and dyspnea to a chronic cough and dyspnea to repetitive hemoptysis with fatigue, anemia, and slowly progressive dyspnea. In some cases, asymptomatic anemia is the only finding present. Contemporary multicenter data demonstrate that anemia is the most prominent presenting feature in children, present in approximately 87% of patients in international pediatric DAH cohorts, while hemoptysis occurs in approximately 42% and is frequently absent in younger children.[4] Higher rates of hemoptysis have been reported in idiopathic pulmonary hemosiderosis-specific cohorts, reflecting heterogeneity across studies.[17] Unexplained iron-deficiency anemia, even without respiratory symptoms, should therefore always prompt evaluation for occult alveolar hemorrhage. In adults, respiratory symptoms tend to be more prominent; however, children present with failure to thrive and anemia.[26]

The classic triad of hemoptysis, iron-deficiency anemia, and diffuse pulmonary infiltrates is present in approximately 79% of adult patients and is frequently incomplete at initial presentation.[5] The mean diagnostic delay in contemporary pediatric cohorts remains approximately 5 months, with the majority of patients initially misdiagnosed.[17] Idiopathic pulmonary hemosiderosis presents in 2 phases. The first, as an acute phase, corresponds with intra-alveolar bleeding episodes associated with cough, dyspnea, hemoptysis, and potentially respiratory failure. The second chronic phase is characterized by the gradual resolution of prior symptoms, with or without treatment. 

Patients who present in the acute phase of the disease show a wide variety of signs and symptoms, including but not limited to respiratory failure, cough, hemoptysis, and worsening anemia. However, many patients may present with a normal physical exam. Rapid asphyxiation due to massive pulmonary hemorrhage has also been reported. Generally, patients who present in the chronic phase of the disease demonstrate exam findings of pallor, emaciation, hepatosplenomegaly, failure to thrive, or even a completely normal exam. In patients with fibrosis, bilateral crackles and finger clubbing may also be present.[2][27] In patients with Lane-Hamilton syndrome, hemoptysis may be the only presenting symptom, with no gastrointestinal manifestations.[8][9] Clinicians should therefore ask specifically about prior celiac disease diagnosis and dietary gluten exposure in all patients with suspected idiopathic pulmonary hemosiderosis.

Evaluation

The evaluation of suspected idiopathic pulmonary hemosiderosis should follow a structured diagnostic approach of exclusion within the broader framework of DAH (see Image. Idiopathic Pulmonary Hemosiderosis Evaluation). The figure illustrates the diagnostic workup of idiopathic pulmonary hemosiderosis as a structured exclusion pathway. Laboratory evaluation (autoimmune panel, celiac serology, core labs) and bronchoscopic/imaging assessment are performed in parallel, converging on lung biopsy when clinically seronegative vasculitis cannot be excluded. Histopathologic confirmation of bland alveolar hemorrhage without capillaritis or immune complex deposition establishes the diagnosis. Whole-exome sequencing is reserved for atypical pediatric cases.

Because DAH represents a common manifestation of diverse conditions, including immune-mediated vasculitis, infection, coagulopathy, cardiac disease, and drug toxicity, no single test confirms idiopathic pulmonary hemosiderosis, and the diagnosis is established only after systematic exclusion of alternative etiologies.

Serologic and Laboratory Evaluation

A comprehensive autoimmune panel is essential and should include ANCA (anti-PR3 and anti-MPO), anti-GBM antibodies, antinuclear antibodies (ANA), anti–double-stranded DNA, extractable nuclear antigens, rheumatoid factor, antiphospholipid antibodies, complement levels (C3, C4), and cryoglobulins. Importantly, seronegative disease does not exclude ANCA-associated vasculitis or pulmonary capillaritis, and tissue confirmation may still be required.

Urinalysis is mandatory to assess for pulmonary–renal syndromes. Findings, eg, hematuria, proteinuria, or red cell casts, should prompt evaluation for anti-GBM disease or ANCA-associated vasculitis and consideration of renal biopsy. Screening for celiac disease should be performed in all patients, regardless of gastrointestinal symptoms, using anti–tissue transglutaminase IgA, total IgA, and anti-endomysial antibodies.[7][8][9] In patients with IgA deficiency, IgG-based testing is required.

Basic laboratory evaluation typically reveals iron-deficiency anemia. Coagulation studies (PT/INR, aPTT, fibrinogen, D-dimer) are necessary to exclude bleeding diatheses. Noninflammatory causes of DAH, including coagulopathies, anticoagulant use, thrombocytopenia, and elevated pulmonary venous pressure, must be systematically excluded. Transthoracic echocardiography is recommended to evaluate for cardiac causes. A detailed medication review is essential to identify potential drug-induced DAH.

Bronchoscopic Evaluation

Bronchoalveolar lavage is a key diagnostic tool and typically demonstrates hemosiderin-laden macrophages and erythrocytes. Importantly, the presence of siderophages supports the diagnosis of DAH but is not specific to idiopathic pulmonary hemosiderosis and may be seen in multiple causes of alveolar hemorrhage.[28] The diagnosis of DAH is supported by progressively bloodier return on sequential lavage aliquots. This finding reflects ongoing alveolar bleeding and is a characteristic feature described in DAH diagnostic frameworks.[29][30]

Perls’ Prussian blue staining is preferred for detecting hemosiderin. Hemosiderin-laden macrophages typically appear 48 to 72 hours after an acute hemorrhagic event; therefore, bronchoalveolar lavage performed very early may yield false-negative results.[30] Microbiologic studies from bronchoalveolar lavage should be performed to exclude infectious causes. A false-negative bronchoalveolar lavage may occur if performed during a quiescent phase between hemorrhagic episodes.

Pulmonary Function Testing and Imaging

Pulmonary function tests typically demonstrate a restrictive pattern. The diffusing capacity for carbon monoxide may be elevated during acute hemorrhage and normal or reduced in chronic disease.[12] Chest radiographs during acute episodes show diffuse alveolar infiltrates, often basilar predominant. High-resolution computed tomography (HRCT) is more sensitive and typically demonstrates ground-glass opacities; chronic disease may show interstitial changes, fibrosis, traction bronchiectasis, or honeycombing.[2][4][31] 

Lung Biopsy

Lung biopsy plays a central role in confirming idiopathic pulmonary hemosiderosis, particularly in adults, where seronegative vasculitis cannot be reliably excluded without histopathology. Biopsy may be obtained via transbronchial, cryobiopsy, or surgical approaches, with surgical biopsy providing the highest diagnostic yield.

The histopathologic pattern of idiopathic pulmonary hemosiderosis consists of hemosiderin-laden macrophages in the absence of capillaritis, neutrophilic infiltration, or immune complex deposition, thereby confirming a diagnosis of “bland” alveolar hemorrhage.[2] Lung biopsy is particularly indicated when clinical suspicion for capillaritis remains despite negative serologic testing, as histopathology is required to distinguish bland alveolar hemorrhage from inflammatory capillaritis.

Advanced and Adjunctive Evaluation

In atypical or severe pediatric cases, genetic evaluation, eg, whole-exome sequencing, may be considered, particularly when syndromic features or immunodeficiency are suspected.[10] Following diagnosis, patients may be categorized into descriptive subgroups based on associated features (eg, autoimmune markers, eosinophilia, renal or multiorgan involvement), which may have implications for prognosis and management.[3]

Treatment / Management

No established gold-standard therapy currently exists for idiopathic pulmonary hemosiderosis, and management strategies rely primarily on observational cohorts, case series, and expert consensus rather than randomized controlled trials. Treatment plans require individualization based on disease severity and the nature of the presentation, whether acute or chronic.

First-Line Therapy

Systemic corticosteroids remain the cornerstone of therapy in both pediatric and adult populations.[32] Acute disease commonly requires initiation of prednisolone at dosages of 0.5 to 0.75 mg/kg/day, up to a maximum of 60 mg/day, followed by gradual tapering after clinical and radiographic improvement occurs.[2] Severe presentations complicated by respiratory failure often necessitate intravenous methylprednisolone pulse therapy at doses of 500 to 2000 mg/day for 3 to 5 days in adults or 20 mg/kg/day in children, followed by transition to oral corticosteroids with tapering to maintenance therapy.[33][34] (B3)

Supportive measures, including blood transfusion, may become necessary in patients with severe anemia or hemodynamic instability. Maintenance therapy frequently involves low-dose corticosteroids at 10 to 15 mg/day in adults or 0.1 to 0.3 mg/kg/day in children. Gradual discontinuation may be considered after 18 to 24 months without recurrence.[35](B3)

Steroid-Sparing and Second-Line Immunosuppressive Therapy

Steroid-sparing immunosuppressive agents are used in refractory, relapsing, or steroid-dependent disease. Commonly used agents include azathioprine, cyclophosphamide, hydroxychloroquine (HCQ), and mycophenolate mofetil.[35][36][37] HCQ is the most frequently used maintenance agent, with approximately 64% of clinicians reporting use in survey data.[35] Combination therapy with corticosteroids, HCQ, and azathioprine has shown favorable outcomes in retrospective studies.[17] A randomized phase 2 trial of HCQ in pediatric interstitial lung disease (chILD), which included only 2 patients with idiopathic pulmonary hemosiderosis, did not demonstrate a statistically significant benefit over placebo for its primary endpoint; therefore, its findings should be interpreted as limited to feasibility and safety rather than efficacy in idiopathic pulmonary hemosiderosis.[38](A1)

Mycophenolate mofetil has demonstrated efficacy in both refractory idiopathic pulmonary hemosiderosis and Lane–Hamilton syndrome.[8][9] However, evidence specific to idiopathic pulmonary hemosiderosis remains limited, and extrapolation from associated conditions should be made cautiously. Other agents, including methotrexate, 6-mercaptopurine, and inhaled corticosteroids, have been used with variable success.[35] Clinicians should be aware of potential adverse effects and drug interactions, particularly with HCQ, including rare neuropsychiatric toxicity and interactions with CYP3A4 inhibitors, eg, clarithromycin.[39] (B3)

Lane–Hamilton Syndrome 

In patients with Lane–Hamilton syndrome, a strict gluten-free diet is essential and may lead to clinical improvement or remission. Immunosuppressive therapy is used similarly to idiopathic pulmonary hemosiderosis but should be combined with dietary management.[7][8][9](B2)

Rescue and Advanced Therapies

Life-threatening hemorrhage may respond to bronchial artery embolization, which has demonstrated high technical and clinical success rates.[40] Extracorporeal membrane oxygenation (ECMO) may provide support for refractory respiratory failure in experienced centers.[41] Emerging and investigational therapies include liposteroid, or liposomal dexamethasone palmitate, a targeted glucocorticoid therapy supported by limited evidence from small series, and mesenchymal stem cell (MSC) therapy, which has shown immunomodulatory effects and remission in small pediatric cohorts.[42] Current evidence for these approaches remains limited to small case series and early-phase investigations, leaving the efficacy and safety of these approaches uncertain in idiopathic pulmonary hemosiderosis.(B2)

Patients with end-stage disease may require lung transplantation. Recurrence within the allograft has been reported, although recurrence does not occur universally, and idiopathic pulmonary hemosiderosis does not represent an absolute contraindication to transplantation.[43]

Differential Diagnosis

Idiopathic pulmonary hemosiderosis is a diagnosis of exclusion within the DAH spectrum. The following categories must be systematically ruled out before idiopathic pulmonary hemosiderosis can be confirmed.

Immune-Mediated and Vasculitic Causes

These are the most critical exclusions, as they require disease-specific therapy and closely mimic idiopathic pulmonary hemosiderosis. ANCA-associated vasculitides, including granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis, are common mimickers. Seronegativity does not exclude the diagnosis; histologic evidence of capillaritis is required. Anti-GBM disease may present with DAH alone or as a pulmonary–renal syndrome and is confirmed by linear IgG deposition on biopsy. Isolated pulmonary capillaritis can also be seronegative and requires biopsy for differentiation from idiopathic pulmonary hemosiderosis. Connective tissue diseases, including systemic lupus erythematosus (SLE), antiphospholipid syndrome, rheumatoid arthritis, Sjögren syndrome, and mixed connective tissue disease (MCTD), should be considered, as should IgA vasculitis, when systemic or renal features are present. COPA syndrome, a rare genetic interferonopathy, should be considered in pediatric patients with refractory or atypical DAH.

Infectious Causes

Infectious DAH typically presents acutely with systemic features but must always be excluded. Relevant pathogens include bacterial organisms (Streptococcus pneumoniae, Staphylococcus aureus, Legionella pneumophila), respiratory viruses (influenza, RSV), opportunistic fungi (Pneumocystis jirovecii, endemic fungi), and mycobacteria (tuberculosis, nontuberculous mycobacteria).

Noninflammatory and Hemodynamic Causes

These produce bland hemorrhage without capillaritis, making them important mimickers of idiopathic pulmonary hemosiderosis. Causes include inherited and acquired coagulopathies (hemophilia, von Willebrand disease, liver disease, vitamin K deficiency), anticoagulant or antiplatelet therapy, and disseminated intravascular coagulation. Cardiac causes, eg, mitral stenosis, left ventricular failure, and elevated pulmonary venous pressure, must be excluded, as should pulmonary veno-occlusive disease and arteriovenous malformations (AVMs). Please see StatPearls' companion resource, "Pulmonary Arteriovenous Malformation," for further information. 

Drug-Induced and Toxic Causes

A thorough medication and exposure history is essential. Implicated agents include amiodarone, nitrofurantoin, infliximab, and penicillamine. E-cigarette or vaping-associated lung injury (EVALI) is an important consideration in adolescents. Inhalational injury, pesticides, and environmental toxins should also be evaluated.

Other Causes and Mimickers

DAH may develop in association with diffuse alveolar damage, acute lung injury syndromes, barotrauma, severe infection, and selected malignant or vascular disorders. Careful evaluation of these alternative etiologies remains essential during diagnostic assessment because multiple pulmonary and systemic conditions can mimic the clinical and radiographic manifestations of DAH. In infants and young children, Heiner syndrome, a cow’s milk protein–associated pulmonary hemosiderosis, requires exclusion before establishing a diagnosis of idiopathic pulmonary hemosiderosis.

An important diagnostic distinction involves Lane–Hamilton syndrome, defined by the coexistence of idiopathic pulmonary hemosiderosis and celiac disease. Lane–Hamilton syndrome does not represent a separate differential diagnosis but rather a clinically significant subtype of idiopathic pulmonary hemosiderosis. All patients with confirmed idiopathic pulmonary hemosiderosis should therefore undergo active screening with celiac serology regardless of the presence or absence of gastrointestinal symptoms.

Prognosis

The prognosis of idiopathic pulmonary hemosiderosis is highly variable, ranging from spontaneous remission to progressive, life-threatening disease. Reported disease duration spans from fulminant cases resulting in death within days to chronic courses extending beyond 2 decades, often complicated by cor pulmonale.

Historical series reported a mean survival of 2.5 to 5 years following diagnosis; however, these data largely reflect the pre-immunosuppression era and underestimate current outcomes. More recent studies demonstrate substantially improved survival, with 5-year survival exceeding 80% to 85% in pediatric patients receiving long-term immunosuppressive therapy[2] and 67% to 84% in adult cohorts.[5][4]

Relapse is common, with approximately 59.4% of pediatric patients experiencing at least one recurrence after initial therapy.[17] Identified risk factors for relapse include lower hemoglobin at presentation and failure to achieve remission within the first 6 months of treatment. Notably, the severity of initial presentation does not reliably predict long-term outcomes.[5] 

Mortality may occur acutely due to massive alveolar hemorrhage or chronically from progressive respiratory insufficiency and right heart failure. Even among long-term survivors, persistent morbidity is common in pediatric DAH cohorts, including patients with idiopathic pulmonary hemosiderosis H, with ongoing lung function impairment and structural abnormalities on high-resolution computed tomography (HRCT) reported in a substantial proportion of patients.[4]

Complications

Complications of idiopathic pulmonary hemosiderosis reflect both recurrent alveolar hemorrhage and the consequences of chronic lung injury and immunosuppressive therapy. Their severity depends on disease burden and frequency of relapse.

The most common complications are iron-deficiency anemia and progressive pulmonary fibrosis, both resulting from repeated hemorrhagic episodes. In the acute setting, complications range from hypoxemia and respiratory distress to life-threatening events, including massive alveolar hemorrhage leading to airway compromise, hemodynamic instability, and death. Chronic disease is associated with progressive respiratory insufficiency and may lead to right heart failure (cor pulmonale).

Additional complications reported in contemporary cohorts include:

• Pulmonary arterial hypertension: Particularly in patients with recurrent exacerbations.[2]
• Bronchiectasis: Detected on high-resolution computed tomography (HRCT) in patients with repeated hemorrhagic injury.[17] 
• Treatment complications: Treatment-related complications, including Cushingoid features, increased infection risk, and vitamin D deficiency, were reported in approximately 21.9% of pediatric patients.[17]